Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 6, 2014, Pages 584-608

  Polso, A K ^a   Lassiter, J L ^a   Nagel, J L ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Antibiotics; Antimicrobials; Obesity; Pharmacodynamic; Pharmacokinetic

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIINFECTIVE AGENT; CIDOFOVIR; COLISTIMETHATE; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FLUCYTOSINE; FOSCARNET; GANCICLOVIR; VANCOMYCIN; VORICONAZOLE;

COST BENEFIT ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; MEDICATION COMPLIANCE; MORBID OBESITY; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; VOLUME OF DISTRIBUTION; ADULT; ANIMAL; BODY WEIGHT; DOSE RESPONSE; HOSPITAL; PATHOPHYSIOLOGY; PHYSIOLOGY; TISSUE DISTRIBUTION;

ADULT; ANIMALS; ANTI-INFECTIVE AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; HOSPITALS; HUMANS; OBESITY, MORBID; PRACTICE GUIDELINES AS TOPIC; TISSUE DISTRIBUTION;

EID: 84912093882     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12200     Document Type: Review

References (70)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief, 2012;82:1-8.
2. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol, 1983;24:643-647.
3. Guerra S, Sherrill DL, Bobadilla A, Martinez FD, Barbee RA. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest, 2002;122:1256-1263.
4. Mancuso P. Obesity and respiratory infections: does excess adiposity weigh down host defense? Pulm Pharmacol Ther, 2013;26:412-419.
5. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis, 2006;6:438-446.
6. Jain R, Chung SM, Jain L et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther, 2011;90:77-89.
7. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet, 2010;49:71-87.
8. Benedek IH, Fiske WD III, Griffen WO, Bell RM, Blouin RA, McNamara PJ. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol, 1983;16:751-754.
9. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet, 2012;51:277-304.
10. Aggarwal N, Porter AC, Tang IY, Becker BN, Akkina SK. Creatinine-based estimations of kidney function are unreliable in obese kidney donors. J Transplant, 2012;2012:872894.
11. Hites M, Taccone FS, Wolff F et al. Case-control study of drug monitoring of beta-lactams in obese critically ill patients. Antimicrob Agents Chemother, 2013;57:708-715.
12. Schwartz SN, Pazin GJ, Lyon JA, Ho M, Pasculle AW. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis, 1978;138:499-505.
13. Blouin RA, Mann HJ, Griffen WO Jr, Bauer LA, Record KE. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther, 1979;26:508-512.
14. Pai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother, 2011;55:4006-4011.
15. Korsager S. Administration o gentamicin to obese patients. Int J Clin Pharmacol Ther Toxicol, 1980;18:549-553.
16. Sketris I, Lesar T, Zaske DE, Cipolle RJ. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol, 1981;21:288-293.
17. Duffull SB, Dooley MJ, Green B, Poole SG, Kirkpatrick CM. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet, 2004;43:1167-1178.
18. Bauer LA, Blouin RA, Griffen WO Jr, Record KE, Bell RM. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm, 1980;37:519-522.
19. Gibbs RS, Blanco JD, Lipscomb KA. Aminoglycoside dosing in obese puerperal women. Am J Obstet Gynecol, 1985;152:89-90.
20. Blouin RA, Brouwer KL, Record KE, Griffen WO Jr, Plezia PM, John W. Amikacin pharmacokinetics in morbidly obese patients undergoing gastric-bypass surgery. Clin Pharm, 1985;4:70-72.
21. Ortega A, Aldaz A, Giraldez J, Brugarolas A. Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours. Pharm World Sci, 1999;21:227-232.
22. Tobramycin. Schaumburg, IL: APP Pharmaceuticals, LLC, 2008.
23. Pogue JM, Lee J, Marchaim D et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis, 2011;53:879-884.
24. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother, 2010;54:4503-4505.
25. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother, 2012;56:2392-2396.
26. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother, 2011;55:3284-3294.
27. Elwood CM, Lucas GD, Muehrcke RC. Acute renal failure associated with sodium colistimethate treatment. Arch Intern Med, 1966;118:326-334.
28. Cubicin (daptomycin). Lexington, MA: Cubist Pharmaceuticals, Inc., 2013.
29. Pai MP, Norenberg JP, Anderson T et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother, 2007;51:2741-2747.
30. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol, 2005;45:48-56.
31. Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother, 2009;53:428-434.
32. Pea F, Cojutti P, Sbrojavacca R et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother, 2011;45:e37.
33. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis, 2010;50:1568-1574.
34. Bookstaver PB, Bland CM, Qureshi ZP et al. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern united states. Pharmacotherapy, 2013;33:1322-1330.
35. Ng J, Schulz L, Rose W et al. Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Antimicrob Agents Chemother, 2014;58:88-93.
36. Synercid (quinupristin and dalfopristin). Greenville, NC: DSM Pharmaceuticals, Inc., 2012.
37. Lefebvre P, Rey J, Morganroth J, Geary W, Montay G. Open, comparative, study of the safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500) in obese and in non-obese male subjects. 20th International Congress of Chemotherapy, Sydney, Australia, 1997, Organising Committee, Vic., Australia.
38. Bactrim (sulfamethoxazole and trimethoprim DS). Philadelphia, PA: AR Scientific, Inc., 2013.
39. Garrett ER, Suverkrup RS, Eberst K, Yost RL, O'Leary JP. Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese. Biopharm Drug Dispos, 1981;2:329.
40. Baxter Healthcare Corporation, ed. Vancomycin hydrochloride [package insert]. Deerfield, IL: Baxter Healthcare Corporation, 2011.
41. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol, 1998;54:621-625.
42. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a bayesian forecasting technique. Antimicrob Agents Chemother, 1993;37:436-440.
43. Penzak SR, Gubbins PO, Rodvold KA, Hickerson SL. Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit, 1998;20:261-265.
44. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother, 1982;21:575-580.
45. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit, 1994;16:513-518.
46. Leong JV, Boro MS, Winter M. Determining vancomycin clearance in an overweight and obese population. Am J Health Syst Pharm, 2011;68:599-603.
47. Reynolds DC, Waite LH, Alexander DP, DeRyke CA. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health Syst Pharm, 2012;69:944-950.
48. Heble DE Jr, McPherson C, Nelson MP, Hunstad DA. Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy, 2013;33:1273-1277.
49. AmBisome (amphotericin B). Northbrook, IL: Astellas Pharma US, Inc., 2012.
50. Vadiei K, Lopez-Berestein G, Luke DR. Disposition and toxicity of amphotericin-B in the hyperlipidemic zucker rat model. Int J Obes, 1990;14:465-472.
51. Groll AH, Mickiene D, Piscitelli SC, Walsh TJ. Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrob Agents Chemother, 2000;44:408-410.
52. Koldin MH, Kobayashi GS, Brajtburg J, Medoff G. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob Agents Chemother, 1985;28:144-145.
53. Ramaswamy M, Peteherych KD, Kennedy AL, Wasan KM. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob Agents Chemother, 2001;45:1184-1191.
54. Gillum JG, Johnson M, Lavoie S, Venitz J. Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Pharmacotherapy, 1995;15:251-253.
55. Pfizer Inc. ed. Vfend. New York, NY: Pfizer, Inc., 2011.
56. Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother, 2011;55:2601-2605.
57. Koselke E, Kraft S, Smith J, Nagel J. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother, 2012;67:2957-2962.
58. Davies-Vorbrodt S, Ito JI, Tegtmeier BR, Dadwal SS, Kriengkauykiat J. Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review. Pharmacotherapy, 2013;33:22-30.
59. Moriyama B, Falade-Nwulia O, Leung J et al. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction. Mycoses, 2011;54:e877-e879.
60. Moriyama B, Jarosinski PF, Figg WD et al. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype. Pharmacotherapy, 2013;33:e19-e22.
61. Dickmeyer NJ, Kiel PJ. Dosing voriconazole in an obese patient. Clin Infect Dis, 2011;53:745.
62. Blum MR, Liao SHT, Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med, 1982;73(Suppl 1A):186.
63. Laskin O. CLinical pharmacokinetics of acyclovir. Clin Pharmacokinet, 1983;8:187.
64. Davis R, Quenzer R, Weller S, Blum R. Acyclovir pharmacokinetics in morbid obesity. Programs and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1991.
65. Hernandez JO, Norstrom J, Wysock G. Acyclovir-induced renal failure in an obese patient. Am J Health Syst Pharm, 2009;66:1288-1291.
66. Seedat A, Winnett G. Acyclovir-induced acute renal failure and the importance of an expanding waist line. BMJ Case Rep, 2012;2012:1-3.
67. Zovirax (acyclovir sodium). Research Triangle Park, NC: GlaxoSmithKline, 2003.
68. Vistide (cidofovir injection). Foster City, CA: Gilead Sciences, Inc., 2000.
69. Foscavir (foscarnet sodium). Wilmington, DE: AstraZeneca, 2012.
70. Cytovene (ganciclovir sodium for injection). Nutley, NJ: Roche Laboratories, Inc., 2006.